Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical instruments maker Harvard Bioscience (NASDAQ:HBIO) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Harvard Bioscience and see what CAPS investors are saying about the stock right now.

Harvard Bioscience facts

Headquarters (founded)

Holliston, Mass. (1901)

Market Cap

$132.3 million


Life sciences tools and services

Trailing-12-Month Revenue

$112.0 million


Chairman/CEO Chane Graziano
CFO Thomas McNaughton

Return on Equity (average, past 3 years)



$20.3 million / $15.3 million


Becton Dickinson
Bio-Rad Laboratories
Thermo Fisher Scientific

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 166 members who have rated Harvard Bioscience believe the stock will outperform the S&P 500 going forward.

This past weekend, one of those bulls, All-Star TMFDeej, helped bring the special opportunity to our community's attention:

Harvard Bioscience is in the process of spinning off its money-losing HART division, leaving behind a manufacturer of scientific instruments trading for only three times earnings, yet growing at 15% to 20% per year. See Jim Royal's great article on the situation for more information.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.